发布求助
文献互助 智能选刊 最新文献

Cancer clinical trials最新文献

筛选
英文 中文
Treatment of cervical carcinoma with methotrexate, bleomycin and vincristine. 甲氨蝶呤、博来霉素和长春新碱治疗宫颈癌。
Cancer clinical trials Pub Date : 1981-01-01
K Behnam, G C Lewis, J H Lee, M H Looka
{"title":"Treatment of cervical carcinoma with methotrexate, bleomycin and vincristine.","authors":"K Behnam,&nbsp;G C Lewis,&nbsp;J H Lee,&nbsp;M H Looka","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Seventeen patients with squamous cell carcinoma of the cervix received a combination of methotrexate, bleomycin, and vincristine. Oral methotrexate and parenteral bleomycin were given every week and intravenous vincristine was given every other week. Eight patients had partial response and one patient had a complete response. This study strongly supports the effectiveness of methotrexate, bleomycin, and vincristine against cervical malignancy.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 1","pages":"75-9"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17229630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy. VP-16-213治疗肺小细胞癌联合化疗失败的疗效观察。
Cancer clinical trials Pub Date : 1981-01-01
M Tempero, A Kessinger, H M Lemon
{"title":"VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.","authors":"M Tempero,&nbsp;A Kessinger,&nbsp;H M Lemon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"155-7"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17327546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma. 美托普林在非小细胞肺癌患者中的II期评价。
Cancer clinical trials Pub Date : 1981-01-01
G R Lynch, R J Gralla, D P Kelsen, E S Casper, M B Stoopler, R B Golbey
{"title":"Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma.","authors":"G R Lynch,&nbsp;R J Gralla,&nbsp;D P Kelsen,&nbsp;E S Casper,&nbsp;M B Stoopler,&nbsp;R B Golbey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A phase II study of metoprine in low dose and in high dose with citrovorum rescue was conducted in patients with non-small-cell lung carcinoma. There were no responses observed in the 36 patients studied, yielding a predicted true response rate of less than 9%. Thrombocytopenia was the dose-limiting toxicity of the low-dose regimen; there was also one episode of leukopenia and sepsis in this group. Although citrovorum rescue obviated hematologic toxicity in the high-dose regimen, mild to moderate neurological toxicity occurred at this dose. Metoprine does not appear to be a useful agent in non-small-cell lung carcinoma when used in the dose schedule employed in this study.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"273-6"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18024005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma. 甲托林联合亚叶酸钙挽救晚期结直肠癌患者的II期评价。
Cancer clinical trials Pub Date : 1981-01-01
G Lynch, V Currie, N Kemeny
{"title":"Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.","authors":"G Lynch,&nbsp;V Currie,&nbsp;N Kemeny","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In a phase II trial 24 patients with measurable metastatic colorectal carcinoma were treated every 2 weeks with high-dose metoprine at 175 mg/m2 and leucovorin rescue. Hematologic toxicity was mild; the limiting toxicity was CNS, occurring in 54% of the patients. No responses were observed, but four patients had disease stabilization. High-dose metoprine with leucovorin rescue appears ineffective in previously treated patients with colorectal carcinoma in the dose and schedule used in this study.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"281-3"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18024006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. 化疗治疗晚期甲状腺癌的现状。
Cancer clinical trials Pub Date : 1981-01-01
D S Poster, S Bruno, J Penta, K Pina, R Catane
{"title":"Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland.","authors":"D S Poster,&nbsp;S Bruno,&nbsp;J Penta,&nbsp;K Pina,&nbsp;R Catane","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An extensive review of the literature was undertaken to identify single agents and chemotherapeutic combinations active against advanced thyroid carcinoma. The two most intensively studied agents were Adriamycin and bleomycin, both of which appear to have definite activity against advanced disease. Studies of 25 other single agents and 17 drug combinations were also reviewed but most of the studies suffered from extremely poor patient accrual, thus precluding statistical analysis. Two cooperative group protocols are in progress which will hopefully accrue enough patients for meaningful interpretation. Physicians treating advanced thyroid carcinoma patients are urged to participate in these studies.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"301-7"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18072613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between time to treatment failure and survival and between time to response and response duration in metastatic breast cancer. Implications for treatment. 转移性乳腺癌治疗失败时间与生存期、反应时间与反应持续时间之间的关系。对治疗的启示。
Cancer clinical trials Pub Date : 1981-01-01
D C Tormey, R S Gelman
{"title":"Relationship between time to treatment failure and survival and between time to response and response duration in metastatic breast cancer. Implications for treatment.","authors":"D C Tormey,&nbsp;R S Gelman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The hypothesis that longer times to response (TTR) and times to treatment failure (TTF) are associated with a more chronic disease resulting in progressively longer response durations (TRTF) and times from treatment failure to death (TFTD) was evaluated in metastatic breast carcinoma. Data from 553 patients across two similar Eastern Cooperative Group combination chemotherapy trials was utilized to evaluate the relationship between TTR and TRTF, and TTF and TFTD. The TTR did not appear to predict for TRTF, which was approximately 7.6 months irrespective of TTR durations from 1 to 6+ months. The TFTD increased to approximately 8 months as the TTF increased to 6 months; thereafter, the TFTD remained stable up to at least 17 months of TTF. The discordance in the results of the two analyses suggests that the operational hypothesis is not necessarily true. However, these data, along with the subset analyses and previous animal and human studies, were taken as evidence that ultimate survival is selected by the response to the first regimen employed, that the primary therapeutic impact of a regimen is in the first 3-6 months, and that the regimen should maximize therapy early to achieve rapid complete remissions.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"355-62"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18080615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemotherapy of disseminated seminoma with combination of cis-diamminedichloroplatinum (II) and cyclophosphamide. 顺式二胺二氯铂(II)联合环磷酰胺治疗弥散性精原细胞瘤。
Cancer clinical trials Pub Date : 1981-01-01
D Vugrin, W J Whitemore, M Batata
{"title":"Chemotherapy of disseminated seminoma with combination of cis-diamminedichloroplatinum (II) and cyclophosphamide.","authors":"D Vugrin,&nbsp;W J Whitemore,&nbsp;M Batata","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nine patients with metastatic seminoma who had received no prior chemotherapy were induced with a combination containing cis-platinum 120 mg/m2 I.V. and cyclophosphamide 600 mg/m2 I.V. for three to six treatments at 4-6 weeks intervals, and then received maintenance with cyclophosphamide 600 mg/m2 I.V. every 3-4 weeks to complete 2 years of chemotherapy. Eight patients entered complete remission: five with chemotherapy alone and three with chemotherapy and radiation or resection of residual disease. Seven patients remain in CR with a minimum follow up of 17 months. Chemotherapy is effective in treatment of metastatic seminoma.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"423-7"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18211915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature. 他莫昔芬治疗不可切除的高肾瘤。II期试验和文献回顾。
Cancer clinical trials Pub Date : 1981-01-01
L Weiselberg, D Budman, V Vinciguerra, P Schulman, T J Degnan
{"title":"Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.","authors":"L Weiselberg,&nbsp;D Budman,&nbsp;V Vinciguerra,&nbsp;P Schulman,&nbsp;T J Degnan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Estrogen receptors have been demonstrated in human hypernephroma (renal cell carcinoma). Antiestrogens have been demonstrated to have antitumor activity in animal models of this disease. A prospective trial of tamoxifen therapy was undertaken in 10 consecutive patients with unresectable hypernephroma. No major responses to tamoxifen were observed. A review of the literature on antiestrogen therapy for this tumor reveals 148 published cases of hypernephroma treated with tamoxifen or nafoxidine. The overall response rate was 7.4%. Antiestrogens appear to have little clinical usefulness in the treatment of advanced hypernephroma.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"195-8"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18262297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintenance management of acute nonlymphocytic leukemia. 急性非淋巴细胞白血病的维持治疗。
Cancer clinical trials Pub Date : 1981-01-01
J P Lewis, T F Pajak, J W Linman, J R Bateman
{"title":"Maintenance management of acute nonlymphocytic leukemia.","authors":"J P Lewis,&nbsp;T F Pajak,&nbsp;J W Linman,&nbsp;J R Bateman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The necessity of intensive maintenance chemotherapy in enhancing the duration of life in patients with acute nonlymphocytic leukemia (ANLL) in remission has been evaluated. Twenty-four patients were managed with maintenance chemotherapy and 24 were not. In patients under 50, there was no evidence that maintenance prolonged survival. In patients over the age of 50, maintenance chemotherapy prolonged survival (p = 0.03). In both groups the duration of first remission appeared to be lengthened in patients on maintenance chemotherapy (p = 0.09). Since patients 50 and older were difficult to reinduce, it appears that the greatest prolongation of life for them is afforded by continuous maintenance chemotherapy which may forestall relapse. On the other hand, patients less than 50 years of age have a high likelihood of achieving a second complete remission; it is in this group that maintenance chemotherapy adds only to morbidity.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"115-24"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18263271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer. m-AMSA, 4'-(9-吖啶胺)甲磺酸-间茴香醚在乳腺癌患者中的II期评估
Cancer clinical trials Pub Date : 1981-01-01
V E Currie, J Howard, R Wittes
{"title":"A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.","authors":"V E Currie,&nbsp;J Howard,&nbsp;R Wittes","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A phase II study of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide was carried out in 40 patients with metastatic carcinoma of the breast. The drug, at a dose of 120 mg/m2, was given as a single intravenous injection every 3 weeks. One patient achieved a partial remission of 4 months duration; three patients experienced minor response. This study suggests that the true major response rate of advanced breast cancer to m-AMSA given in this manner is less than 13% at the 95% confidence level.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"249-51"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17944207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信